Carlotta Ronchi obtained her PhD from the University of Milano – Bicocca. During her PhD, where she investigated the role of dysregulated Late Na+ current  (INaL ) in of cardiac ischemia/reperfusion damage. Her contribution defined the central role exerted by mitochondrial Ca2+ in setting the severity of the ischemic damage.

After the PhD, she continued her work at the University of Milano – Bicocca, investigating the role of genetic modifiers in the phenotypic variability in arrhythmogenic KCNQ1 mutations associated to the Long QT Syndrome, using patient-specific human induced pluripotent stem cells derived cardiomyocytes. Her research also was focused to characterize the electrophysiological phenotype of patient-specific and CRISPR/Cas9 gene-edited iPSC-derived cardiomyocytes carrying variants associated with a rare malignant cardiomyopathy. Within this project, her have identified an effective therapy with potential translational relevance to patients.  

During her PostDoc at Isituto Italiano di Tecnologia, she participated to European project Lion Hearted Project (2020 FETOPEN 2018-2020) which aimed to identify novel physiological approaches for cardiovascular diseases and cardiovascular repair based on light-sensitive polymers. Her contribution is focused to optically control the proliferation and function of cardiac and vascular cells to reactive the damaged cardiac cells to restore their function and inducing new vessel formation.

Since November 2022, Carlotta has been part of Elisa Di Pasquale’s group at Humanitas Research Hospital, where she uses iPSC-derived cardiac cells to model laminopathy-associated cardiomyopathies. Her research focuses on developing human in vitro cardiac models to uncover disease mechanisms and identify therapeutic targets. She investigates LMNA-related cardiomyopathies by studying Lamin functions in different cardiomyocyte subtypes, transcriptional regulation of cell-specific phenotypes, and the role of the Lamin A/C-interacting protein MLIP as a potential disease modifier, combining patient-derived iPSCs with single-cell and 3D functional analyses to discover new therapeutic strategies.